Autonomous Reanimation and Evacuation (AREVA) Research Program

AREVA Logo

AREVA prioritizes translational research focusing on combat-relevant trauma and novel critical care interventions during care at ground level and high altitude, using a multi-disciplinary physician-led research team.

Mission: To enable research-to-practice translation of novel life-saving interventions in critical care via performance of clinically relevant translational trauma models followed by clinical trials.

Current Focus Area: Wearable medical solutions, polytrauma, critical care, extracorporeal life support (ECLS), autonomous integrated critical care systems for sustainment of life during ground and aeromedical manned and unmanned evacuation of critically ill.

The AREVA Team

Andriy “Andrew” Batchinsky, MD, Founder and Director, AREVA
Teryn Roberts, PhD, Principal Investigator
Yanyi Zang, PhD, Co-Investigator
Antoine Persello, PhD, Co-Investigator
George Harea, PhD Candidate
Daniel Wendorf, Laboratory Manager
Brendan Beely, RRT, Research Coordinator

Learn more

Performance Capabilities

AREVA is a research program and laboratory servicing 12 combat casualty care-relevant research grants carried out at prolonged field-care intensive care unit studies for 72 hours. AREVA executes benchtop science and ex vivo experiments up to 24 hours in duration in a dedicated plug-and-play circulation laboratory. AREVA performs large animal trauma studies with up to 96 hours of round-the-clock intensive care, conducted to human ICU standards of care. With a state-of-the-art coagulation laboratory and dedicated clinical diagnostic laboratory tools and point-of-care devices, AREVA can perform all phases of study from concept design through injured and un-injured large animal experiments.

Current Projects

  • Development of wearable critical care systems
  • Minimal invasive mobile expeditionary trauma management solutions
  • Clinically relevant realistic translational trauma models for testing of new treatments of trauma and single (lung, kidney, heart, brain) and multiorgan failure
  • Optimal management of patients with TBI and severe multisystem organ failure using novel forms of ECLS and treatment protocols
  • Development of blood-friendly blood-polymer interfaces for heparin-free biologically friendly ECLS
  • Reduction in invasiveness and use of mechanical ventilation in respiratory failure of any kind using extracorporeal CO2 removal and oxygenation carried out in conjunction or instead of mechanical ventilation
  • Development of expeditionary and autonomous critical care solutions for life sustainment during care in place, evacuation delays for up to 72 hours, and manned and unmanned ground and aeromedical evacuation
  • Organ and limb perfusion systems
  • Animal Intensive Care Unit

    The animal intensive care unit is made of a fully self-enclosed space with dedicated HEPA filtration. It is equipped with state-of-the-art ICU patient care equipment to provide round-the-clock care to human standards of care. The Animal ICU is currently built to conduct two large animal experiments simultaneously, with plans for future expansion to 4 beds, including BSL 2 capability.

    LEARN MORE

    Unique Research Areas

    syringe

    Small and Large Animal Research

    Point of Injuries Interventions

    Point-of-care Testing

    Ex-vivo and In-vivo Research

    human heart

    Selective organ perfusion

    AREVA applies ECLS therapy to organs and traumatically amputated limbs to enable a longer time before re-attachment. This novel work is conducted in a plug-and-play ex vivo circulation laboratory using donor blood.

    All Forms of ECLS

    AREVA is investigating earlier and wider applications of ECLS technologies in various configurations to improve patient outcomes.

    Examining blood sample in laboratory

    Anticoagulation Research

    AREVA tests ground-breaking ideas and approaches to limit or remove anticoagulation and make biologically friendly interfaces suitable without the need to administer any anticlotting agents.

    Infection and Inflammation Research

    Pre-clinical Multi-day Studies

    Pre-FDA and GLP Research

    Clinical Trials

    Army soldier shooting rifle while covering colleagues on smoky battlefield

    Combat Relevant Research

    AREVA is committed to reducing mortality in combat casualties by examining the most severe non-survivable injuries.

    plane flying over snow

    Arctic Medicine

    AREVA Collaborations

    AREVA has a strong record of successful collaborations with universities, companies, government agencies, clinical care teams, and industry leaders at all phases of research.

    Collaborate with AREVA

    Government

  • U.S. Special Operations Command
  • Uniformed Services University
  • U.S. Army Telemedicine and Advanced Technology Research Center
  • U.S. Army Institute for Chemical Defense
  • U.S. Army Institute of Surgical Research
  • Defense Health Agency
  • Food and Drug Administration
  • U.S. Army Burn Center, San Antonio
  • Academic

  • Harvard University
  • Mass General Hospital
  • University of Siena
  • University of Milan
  • University of Georgia
  • Colorado State University
  • University of the Incarnate Word
  • University of the Incarnate Word School of Osteopathic Medicine
  • University of Texas Health Science Center, San Antonio
  • University of Texas, San Antonio
  • University of California, Irvine, Beckman Laser Institute
  • University of South Florida, Tampa
  • COMMERCIAL & CLINICAL

  • Xenios/Fresenius
  • Maquet/Getinge
  • KBR Labortories – Houston, TX
  • Cytosorbents
  • Thornhill Medical
  • Hamilton Medical
  • Draeger
  • Draper Labs
  • Methodist Hospital, San Antonio, TX
  • Mayo Clinic, Manchester, MN
  • INOVA Medical, VA, Department of Pulmonary Clinical Care
  • Scientific Publications

    Geneva researchers at AREVA have published scientific publications in areas including Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Life Support, Combat Care, Regenerative Medicine, Trauma Care, Wound Healing and more.

    Learn More